The genomics market in Germany is expected to reach a projected revenue of US$ 2,763.3 million by 2033. A compound annual growth rate of 21.5% is expected of Germany genomics market from 2026 to 2033.
Agilent Technologies Inc, Bio-Rad Laboratories Inc, Danaher Corp, Eppendorf, Eurofins Scientific SE, Roche Holding AG ADR, GE Aerospace, Illumina Inc, Myriad Genetics Inc, Oxford Nanopore Technologies PLC, Pacific Biosciences of California Inc, Qiagen NV, Quest Diagnostics Inc, Thermo Fisher Scientific Inc, 23andMe Holding Co Class A
Other key industry trends
In terms of revenue, Germany accounted for 3.1% of the genomics market in 2025.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In Europe, Spain genomics market is projected to lead the regional market in terms of revenue in 2033.
Germany is the fastest growing regional market in Europe and is projected to reach USD 2,763.3 million by 2033.
According to Robert Koch Institute, in Germany, each year 480,000 people are diagnosed with cancer, which increases the need for rapid diagnostics. An in-depth analysis of genome of cancerous cells is important for optimal understanding of diseases to advance treatment.
Hence, the German Cancer Consortium, in association with German Cancer Research, invested in the Illumina HiSeq X sequencing solution in 2015. With the ability to sequence more than 18,000 genomes annually, it is the first and most innovative technology in the world to provide complete coverage of the human entire genome for under EUR 1,000 per genome.
Such devices can enable scientists to detect all cancer-related genetic variations in the shortest time. These factors are anticipated to lead to substantial growth of the market over the forecast period.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Genomics Market Outlook will help companies and investors design strategic landscapes.
Functional Genomics was the largest segment with a revenue share of 34.95% in 2025.
Horizon Databook has segmented the Germany genomics market based on functional genomics, epigenomics, pathway analysis, biomarker discovery covering the revenue growth of each sub-segment from 2021 to 2033.
According to Robert Koch Institute, in Germany, each year 480,000 people are diagnosed with cancer, which increases the need for rapid diagnostics. An in-depth analysis of genome of cancerous cells is important for optimal understanding of diseases to advance treatment.
Hence, the German Cancer Consortium, in association with German Cancer Research, invested in the Illumina HiSeq X sequencing solution in 2015. With the ability to sequence more than 18,000 genomes annually, it is the first and most innovative technology in the world to provide complete coverage of the human entire genome for under EUR 1,000 per genome.
Such devices can enable scientists to detect all cancer-related genetic variations in the shortest time. These factors are anticipated to lead to substantial growth of the market over the forecast period.
Germany Genomics Market Application Outlook (Revenue, USD Million , 2021-2033)
Functional Genomics
Epigenomics
Pathway Analysis
Biomarker Discovery
Others
Germany Genomics Market Deliverable Outlook (Revenue, USD Million , 2021-2033)
Products
Services
Germany Genomics Market End Use Outlook (Revenue, USD Million , 2021-2033)
Pharmaceutical and Biotechnology Companies
Hospitals and Clinics
Academic and Government Institutes
Clinical Research
Other End Users
Reasons to subscribe to Genomics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Genomics Market Outlook databook
Our clientele includes a mix of Genomics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany Genomics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Germany Genomics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.